Reduction of Early mortaLITY in HIV-infected African adults and children starting antiretroviral therapy: REALITY trial. (360G-Wellcome-096465_Z_11_Z)

£793,577

The principalresearch question is how best to reduce excess early mortality in African HIV-infected adults andchildren initiating ART. Reasons for high early mortality are multi-factorial, including high rates ofco-infections (TB, bacterial infections, fungal/protozoal infections, parasites), immunereconstitution inflammatory syndrome (IRIS), malnutrition and advanced HIV infection. Severalinterventions might therefore reduce early mortality in HIV-infected patients startingART with low CD4, and could form part of a highly effective integrated care "bundle".

Where is this data from?

This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.

Grant Details

Amount Awarded 793577
Applicant Surname Gibb
Approval Committee Joint Global Health Trials Committee
Award Date 2011-05-16T00:00:00+00:00
Financial Year 2010/11
Grant Programme: Title Joint Global Health Trials Award
Internal ID 096465/Z/11/Z
Lead Applicant Prof Diana Gibb
Partnership Name Joint Global Health Trials
Partnership Value 793577
Planned Dates: End Date 2015-06-30T00:00:00+00:00
Planned Dates: Start Date 2012-01-01T00:00:00+00:00
Recipient Org: Country United Kingdom
Region South West